首页> 美国卫生研究院文献>Infection and Immunity >Precolonized Human Commensal Escherichia coli Strains Serve as a Barrier to E. coli O157:H7 Growth in the Streptomycin-Treated Mouse Intestine
【2h】

Precolonized Human Commensal Escherichia coli Strains Serve as a Barrier to E. coli O157:H7 Growth in the Streptomycin-Treated Mouse Intestine

机译:预先定殖的人类共生大肠杆菌菌株可作为链霉素处理过的小鼠肠道中大肠杆菌O157:H7生长的屏障

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Different Escherichia coli strains generally have the same metabolic capacity for growth on sugars in vitro, but they appear to use different sugars in the streptomycin-treated mouse intestine (Fabich et al., Infect. Immun. 76:1143-1152, 2008). Here, mice were precolonized with any of three human commensal strains (E. coli MG1655, E. coli HS, or E. coli Nissle 1917) and 10 days later were fed 105 CFU of the same strains. While each precolonized strain nearly eliminated its isogenic strain, confirming that colonization resistance can be modeled in mice, each allowed growth of the other commensal strains to higher numbers, consistent with different commensal E. coli strains using different nutrients in the intestine. Mice were also precolonized with any of five commensal E. coli strains for 10 days and then were fed 105 CFU of E. coli EDL933, an O157:H7 pathogen. E. coli Nissle 1917 and E. coli EFC1 limited growth of E. coli EDL933 in the intestine (103 to 104 CFU/gram of feces), whereas E. coli MG1655, E. coli HS, and E. coli EFC2 allowed growth to higher numbers (106 to 107 CFU/gram of feces). Importantly, when E. coli EDL933 was fed to mice previously co-colonized with three E. coli strains (MG1655, HS, and Nissle 1917), it was eliminated from the intestine (<10 CFU/gram of feces). These results confirm that commensal E. coli strains can provide a barrier to infection and suggest that it may be possible to construct E. coli probiotic strains that prevent growth of pathogenic E. coli strains in the intestine.
机译:不同的大肠杆菌菌株通常具有相同的代谢能力,以在体外糖上生长,但是它们似乎在链霉素处理的小鼠肠中使用不同的糖(Fabich等,Infect.Immun.76:1143-1152,2008)。在这里,将小鼠与三种人类共生株(大肠杆菌MG1655,大肠杆菌HS或大肠杆菌Nissle 1917)进行预克隆,并在10天后给它们喂10 5 相同菌株的CFU。 。尽管每个预先定殖的菌株几乎消除了其同基因菌株,从而证实可以在小鼠中模拟定植抗性,但是每个菌株都允许其他共生菌株生长到更高的数量,这与在肠道中使用不同营养素的不同共生大肠杆菌菌株一致。还用5种共生大肠杆菌菌株对小鼠进行预定殖10天,然后喂食10×5 大肠杆菌EDL933(一种O157:H7病原体)的CFU。大肠杆菌Nissle 1917和大肠杆菌EFC1限制了大肠杆菌EDL933在肠中的生长(10 3 至10 4 CFU /克粪便),而E.大肠杆菌MG1655,大肠杆菌HS和大肠杆菌EFC2允许增长到更高的数量(每克粪便10 6 至10 7 CFU)。重要的是,当将大肠杆菌EDL933喂给先前与三种大肠杆菌菌株(MG1655,HS和Nissle 1917)共定殖的小鼠时,它就从肠中清除了(<10 CFU /克粪便)。这些结果证实,普通的大肠杆菌菌株可以提供感染的屏障,并表明可能构建 E。阻止致病性 E生长的大肠杆菌益生菌菌株。肠中的大肠杆菌菌株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号